Back to top
more

Echo Therapeutics (ECTE)

(Delayed Data from OTC)

$0.00 USD

0.00
NA

0.00 (0.00%)

Updated Sep 2, 2021 03:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 252)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ECTE

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Echo Therapeutics Inc. [ECTE]

Reports for Purchase

Showing records 1 - 20 ( 30 total )

Company: Echo Therapeutics Inc.

Industry: Medical - Instruments

Record: 1

09/18/2014

Company Report

Pages: 5

Platinum intends to file lawsuit against Echo - dropping coverage

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 10.00

Research Provided by a Third Party

Company: Echo Therapeutics Inc.

Industry: Medical - Instruments

Record: 2

08/21/2014

Company Report

Pages: 7

Reported Q2, Platinum holds conference call

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Echo Therapeutics Inc.

Industry: Medical - Instruments

Record: 3

05/12/2014

Company Report

Pages: 7

Reported Q1 results

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Echo Therapeutics Inc.

Industry: Medical - Instruments

Record: 4

12/11/2013

Company Report

Pages: 7

Strategic China partnership and $10 million cash infusion announced

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Echo Therapeutics Inc.

Industry: Medical - Instruments

Record: 5

11/26/2013

Company Report

Pages: 7

Reported impressive Symphony CE Mark study results, raising PT to $9.35

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Echo Therapeutics Inc.

Industry: Medical - Instruments

Record: 6

11/08/2013

Company Report

Pages: 7

Echo reports Q3, CE Mark study results expected in a few weeks

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Echo Therapeutics Inc.

Industry: Medical - Instruments

Record: 7

10/04/2013

Company Report

Pages: 7

Delays, delays, delays - do we hear an Echo? Forthrightness refreshing, however...

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Echo Therapeutics Inc.

Industry: Medical - Instruments

Record: 8

08/28/2013

Company Report

Pages: 7

CEO Mooney on immediate leave of absence, EU approval on track for year-end

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Echo Therapeutics Inc.

Industry: Medical - Instruments

Record: 9

08/12/2013

Company Report

Pages: 7

Reports Q2, CE Mark study still progressing

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Echo Therapeutics Inc.

Industry: Medical - Instruments

Record: 10

06/07/2013

Company Report

Pages: 7

Conducts 1-for-10 reverse split, updating numbers

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Echo Therapeutics Inc.

Industry: Medical - Instruments

Record: 11

05/13/2013

Company Report

Pages: 8

Releases Q1 results, design freeze achieved, waiting on IRBs

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Echo Therapeutics Inc.

Industry: Medical - Instruments

Record: 12

03/19/2013

Company Report

Pages: 7

Releases Q4 results, plans for an eventful 2013

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Echo Therapeutics Inc.

Industry: Medical - Instruments

Record: 13

02/12/2013

Company Report

Pages: 11

New funding should carry Echo through approval - critical care CGM thoughts

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Echo Therapeutics Inc.

Industry: Medical - Instruments

Record: 14

11/08/2012

Company Report

Pages: 7

Reports Q3 2012 results ahead of estimates, gears up for Symphony

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Echo Therapeutics Inc.

Industry: Medical - Instruments

Record: 15

08/13/2012

Company Report

Pages: 7

ECTE Echo reported Q2 2012 results, credit facility announced

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Echo Therapeutics Inc.

Industry: Medical - Instruments

Record: 16

08/01/2012

Company Report

Pages: 9

ECTE Echo announces positive results in second leg of critical care pilot study

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Echo Therapeutics Inc.

Industry: Medical - Instruments

Record: 17

07/12/2012

Company Report

Pages: 7

Prelude licensing agreement expanded

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Echo Therapeutics Inc.

Industry: Medical - Instruments

Record: 18

06/11/2012

Company Report

Pages: 7

ECTE Echo at the American Diabetes Association Scientific Sessions

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Echo Therapeutics Inc.

Industry: Medical - Instruments

Record: 19

05/14/2012

Company Report

Pages: 7

ECTE Echo announces inline Q1 2012 results; lowering rating and price target

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Echo Therapeutics Inc.

Industry: Medical - Instruments

Record: 20

05/02/2012

Company Report

Pages: 9

ECTE Echo announces positive results in critical care pilot study

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party